Ocugen Doses First Patient in Phase 3 ArMaDa3 Trial of OCU410 for Geographic Atrophy

Advancing an AAV5-based subretinal gene therapy through a single pivotal trial to BLA carries significant CMC and regulatory weight, and Ocugen's initiation of ArMaDa3 puts those pressures into sharp relief. The company dosed the first patient in its global phase 3 registrational trial of OCU410 for geographic atrophy (GA) secondary to dry age-related macular degeneration, weeks after FDA granted RMAT designation on July 29, 2026.

RMAT status opens rolling review and more frequent CBER engagement, but it also raises the bar on manufacturing readiness. For CMC leads, a single 200 µL subretinal injection per subject means process consistency, viral vector titre, and fill-finish precision must be locked well ahead of the BLA filing Ocugen is targeting for 2028. Scale-up timelines for AAV5 are not forgiving, and a 237-subject global trial across the US, Canada, Europe, and Latin America will stress-test supply chain assumptions early.

The phase 3 design followed a Type B end-of-phase 2 meeting with CBER in July 2026, which produced alignment on primary and secondary endpoints, dose selection, adaptive design, and the single adequate and well-controlled trial pathway. That alignment is consequential: a single pivotal study supporting a BLA requires robust statistical architecture and endpoint defensibility from the outset. The primary endpoint is rate of change of square root-transformed GA lesion area by fundus autofluorescence at months 4, 8, and 12, analyzed by mixed model for repeated measures. Secondary endpoints include low-luminance visual acuity loss and ellipsoid zone area loss by spectral-domain optical coherence tomography.

Phase 2 ArMaDa data (NCT06018558, 51 subjects) underpin the registrational program. In the medium dose cohort, within the pivotal population defined by lesion size of 2.5 to 17.5 mm², GA lesion growth rate was reduced by 31% versus control at 12 months (P <.05). Ellipsoid zone area loss was reduced by 27% in the same group. Ocugen characterises this as approximately twice the treatment benefit reported for currently approved complement inhibitors at comparable timepoints. OCU410 targets four pathophysiological drivers simultaneously, complement overactivation, chronic inflammation, oxidative stress, and lipid dysregulation, via a single administration, differentiating it mechanistically from approved agents requiring repeated intravitreal dosing.

Ocugen is also in discussions with the European Medicines Agency on potential alignment to support a marketing authorisation application using the same trial, a dual-jurisdiction strategy that will require careful attention to divergent data package expectations and GMP site qualification across supply regions.

The BLA filing anticipated in 2028 sets a firm horizon against which manufacturing scale-up, process validation, and CBER inspection readiness will need to be sequenced.

Source: CGTLive via cgtlive.com, September 8, 2026.